RESUMO
The use of a combination of intrapleural fibrinolytics or tissue plasminogen activator(tPA) Alteplase and deoxyribonuclease (Dnase) has been increasing for cases of complicated pleural infection/parapneumonic effusion worldwide. Its efficacy and success rate in selected cases of complicated parapneumonic effusion unresponsive to antibiotics and chest drainage are well documented. This case report demonstrates the first use of combination intrapleural fibrinolytic (Alteplase) and DNAse (Pulmozyme) in Malaysia for a case of pleural infection/parapneumonic effusion.
Assuntos
Desoxirribonucleases/uso terapêutico , Fibrinolíticos/uso terapêutico , Doenças Pleurais/tratamento farmacológico , Infecções Respiratórias/tratamento farmacológico , Ativador de Plasminogênio Tecidual/uso terapêutico , Adulto , Desoxirribonucleases/administração & dosagem , Quimioterapia Combinada , Fibrinolíticos/administração & dosagem , Humanos , Malásia , Masculino , Doenças Pleurais/diagnóstico por imagem , Radiografia Torácica , Infecções Respiratórias/diagnóstico por imagem , Ativador de Plasminogênio Tecidual/administração & dosagemRESUMO
Clinical experience with extensively Drug Resistant tuberculosis (XDR-TB) has not been reported in Malaysia before. We describe the clinical characteristics, risk factors, progress and therapeutic regimen for a healthcare worker with XDR-TB, who had failed therapy for multidrug resistant TB (MDR TB) in our institution. This case illustrates the risk of TB among healthcare workers in high TB-burden settings, the importance of obtaining upfront culture and susceptibility results in all new TB cases, the problem of acquired drug resistance developing during MDR-TB treatment, the challenges associated with XDR-TB treatment regimens, the value of surgical resection in refractory cases, and the major quality of life impact this disease can have on young, economically productive individuals.